米国の抗ウイルス薬市場規模、シェア、動向分析レポート：タイプ別、薬剤クラス別、流通チャネル別、セグメント別予測、2025年～2030年

米国の抗ウイルス薬市場サマリー

米国の抗ウイルス薬市場規模は2024年に264億1,000万米ドルと推計され、2030年には236億1,000万米ドルに達すると予測され、2025年から2030年までのCAGRは-1%で成長すると予測されます。この減少は、COVID-19に特異的な抗ウイルス薬に対する需要が減退していることが主な原因であり、2025年にはCOVID-19の重症患者数と関連する入院患者数が大幅に減少しているためです。

HIV、B型およびC型肝炎、ヘルペス、インフルエンザの治療が主に抗ウイルス薬の米国市場を牽引しています。CDCは、米国では約12億人がHIVに、24億人がC型肝炎に、85万人がB型肝炎に罹患していると推定しています。CDCの報告によると、インフルエンザ、COVID-19、RSVを含む急性呼吸器疾患は、2025年半ば現在、米国では非常に低いレベルにとどまっており、抗ウイルス薬に対する当面の需要が減少しています。この発生率の低さは、症状緩和や免疫サポートのための補完医療アプローチの利用の増加と相まって、抗ウイルス薬市場の成長を緩やかにしています。

例えば、C型肝炎治療薬ソバルディは1錠あたり約1,000米ドルであり、12週間服用した場合の総治療費は約84,000米ドルとなります。同様に、オリシオの1ヶ月の治療費は23,600米ドルで、治療期間は最長48週間と見積もられています。

米国食品医薬品局（FDA）による規制監督は、抗ウイルス薬業界の形成に不可欠な役割を果たしています。FDAの厳格な承認プロセスにより安全性と有効性が保証され、最近の承認では併用療法と小児適応が重視されています。2025年6月、FDAは3歳以上の小児のC型急性肝炎に対するマヴィレットの使用拡大を承認しました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 米国の抗ウイルス薬市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• 米国の抗ウイルス薬市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析
• 米国の抗ウイルス薬市場：パイプライン分析

第4章 米国の抗ウイルス薬市場：タイプ別推定・動向分析

• タイプセグメントダッシュボード
• 米国の抗ウイルス薬市場：タイプ別変動分析
• 米国の抗ウイルス薬市場規模と動向分析（タイプ別、2018～2030年）
• ブランド
• ジェネリック医薬品

第5章 米国の抗ウイルス薬市場：薬剤クラスの推定・動向分析

• 薬物クラスセグメントダッシュボード
• 米国の抗ウイルス薬市場：薬剤クラスの変動分析
• 米国の抗ウイルス薬市場規模と動向分析（薬剤クラス別、2018～2030年）
• DNAポリメラーゼ阻害剤
• 逆転写酵素阻害剤
• プロテアーゼ阻害剤
• ノイラミニダーゼ阻害剤
• その他

第6章 米国の抗ウイルス薬市場：用途推定・動向分析

• アプリケーションセグメントダッシュボード
• 米国の抗ウイルス薬市場：申請変動分析
• 米国の抗ウイルス薬市場規模と動向分析（用途別、2018～2030年）
• HIV
• 肝炎
• ヘルペス
• インフルエンザ
• その他

第7章 米国の抗ウイルス薬市場：流通チャネルの推定・動向分析

• 流通チャネルセグメントダッシュボード
• 米国の抗ウイルス薬市場：流通チャネル変動分析
• 米国の抗ウイルス薬市場規模と動向分析（流通チャネル別、2018～2030年）
• 病院薬局
• 小売薬局
• オンライン薬局

第8章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業/競合の分類
• ベンダー情勢
  • Key company heat map analysis, 2024
• 企業プロファイル
  • F. Hoffmann-La Roche Ltd.
  • GSK plc.
  • AbbVie, Inc.
  • Merck &Co., Inc.
  • Johnson &Johnson Services, Inc.
  • Bristol-Myers Squibb Company
  • Cipla Inc.
  • Aurobindo Pharma
  • Dr. Reddy's Laboratories Ltd.
  • ADARx Pharmaceuticals Inc.

List of Tables

• Table 1 List of Abbreviations
• Table 2 U.S. Antiviral Drugs Market 2018 - 2030 (USD Billion)
• Table 3 U.S. Antiviral Drugs Market, by Type, 2018 - 2030 (USD Billion)
• Table 4 U.S. Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
• Table 5 U.S. Antiviral Drugs Market, by Application, 2018 - 2030 (USD Billion)
• Table 6 U.S. Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Market research approaches
• Fig. 5 QFD modeling for market share assessment
• Fig. 6 Information Procurement
• Fig. 7 Market Formulation and Validation
• Fig. 8 Data Validating & Publishing
• Fig. 9 Market Segmentation & Scope
• Fig. 10 U.S. Antiviral Drugs Market Snapshot
• Fig. 11 Type Segment Snapshot
• Fig. 12 Drug Class Segment Snapshot
• Fig. 13 Application Segment Snapshot
• Fig. 14 Distribution Channel Segment Snapshot
• Fig. 15 Competitive Landscape Snapshot
• Fig. 16 Parent market outlook
• Fig. 17 U.S. Antiviral Drugs Market Value, 2024 (USD Billion)
• Fig. 18 U.S. Antiviral Drugs Market - Value Chain Analysis
• Fig. 19 U.S. Antiviral Drugs Market - Market Dynamics
• Fig. 20 U.S. Antiviral Drugs Market - PORTER's Analysis
• Fig. 21 U.S. Antiviral Drugs Market - PESTEL Analysis
• Fig. 22 U.S. Antiviral Drugs Market Estimates & Forecasts, By Type: Key Takeaways
• Fig. 23 U.S. Antiviral Drugs Market Share, By Type, 2024 & 2030
• Fig. 24 Branded Market Estimates & Forecasts, 2018 - 2030 (USD Billion)
• Fig. 25 Generics Market Estimates & Forecasts, 2018 - 2030 (USD Billion)
• Fig. 26 U.S. Antiviral Drugs Market Estimates & Forecasts, By Drug Class: Key Takeaways
• Fig. 27 U.S. Antiviral Drugs Market Share, By Drug Class, 2024 & 2030
• Fig. 28 DNA Polymerase Inhibitors Market Estimates & Forecasts, 2018 - 2030 (USD Billion)
• Fig. 29 Reverse Transcriptase Inhibitors Market Estimates & Forecasts, 2018 - 2030 (USD Billion)
• Fig. 30 Protease Inhibitors Market Estimates & Forecasts, 2018 - 2030 (USD Billion)
• Fig. 31 Neuraminidase Inhibitors Market Estimates & Forecasts, 2018 - 2030 (USD Billion)
• Fig. 32 Other Drug Class Market Estimates & Forecasts, 2018 - 2030 (USD Billion)
• Fig. 33 U.S. Antiviral Drugs Market Estimates & Forecasts, By Application: Key Takeaways
• Fig. 34 U.S. Antiviral Drugs Market Share, By Application, 2024 & 2030
• Fig. 35 HIV Market Estimates & Forecasts, 2018 - 2030 (USD Billion)
• Fig. 36 Hepatitis Market Estimates & Forecasts, 2018 - 2030 (USD Billion)
• Fig. 37 Herpes Market Estimates & Forecasts, 2018 - 2030 (USD Billion)
• Fig. 38 Influenza Market Estimates & Forecasts, 2018 - 2030 (USD Billion)
• Fig. 39 Other Applications Market Estimates & Forecasts, 2018 - 2030 (USD Billion)
• Fig. 40 U.S. Antiviral Drugs Market Estimates & Forecasts, By Distribution Channel: Key Takeaways
• Fig. 41 U.S. Antiviral Drugs Market Share, By Distribution Channel, 2024 & 2030
• Fig. 42 Hospital Pharmacy Market Estimates & Forecasts, 2018 - 2030 (USD Billion)
• Fig. 43 Retail Pharmacy Market Estimates & Forecasts, 2018 - 2030 (USD Billion)
• Fig. 44 Online Pharmacy Market Estimates & Forecasts, 2018 - 2030 (USD Billion)
• Fig. 45 Key Company Categorization
• Fig. 46 Company Market Positioning
• Fig. 47 Strategy Mapping

U.S. Antiviral Drugs Market Summary

The U.S. antiviral drugs market size was estimated at USD 26.41 billion in 2024 and is projected to reach USD 23.61 billion by 2030, growing at a CAGR of -1% from 2025 to 2030. This decline is largely due to the waning demand for COVID-19-specific antivirals, as the number of severe COVID-19 cases and related hospitalizations has dropped significantly in 2025.

Treatments for HIV, hepatitis B and C, herpes, and influenza primarily drive the U.S. market for antiviral drugs. The CDC estimates that about 1.2 billion people in the U.S. are living with HIV, 2.4 billion with hepatitis C, and 850,000 with hepatitis B. The CDC reports that acute respiratory illnesses, including influenza, COVID-19, and RSV, remain at very low levels in the U.S. as of mid-2025, reducing the immediate demand for antiviral medications. This low incidence, combined with the growing use of complementary health approaches for symptom relief and immune support, has moderated the growth of the antiviral drugs market.

Despite these advancements, the high cost of antiviral treatments remains a significant challenge for many patients and healthcare systems in the U.S. For instance, the hepatitis C drug Sovaldi costs approximately USD 1,000 per pill, resulting in a total treatment cost of around USD 84,000 for a 12-week course . Similarly, Olysio's monthly treatment cost is estimated at USD 23,600, with treatment durations extending up to 48 weeks.

Regulatory oversight by the U.S. Food and Drug Administration (FDA) plays an essential role in shaping the antiviral drugs industry. The FDA's rigorous approval process ensures safety and efficacy, with recent approvals emphasizing combination therapies and pediatric indications. In June 2025, the FDA approved the expanded use of Mavyret for acute hepatitis C in children aged 3 and above.

U.S. Antiviral Drugs Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global U.S. antiviral drugs industry report based on type, drug class, application, and distribution channel.

• Type Outlook (Revenue, USD Billion, 2018 - 2030)
• Branded
• Generics
• Drug Class Outlook (Revenue, USD Billion, 2018 - 2030)
• DNA Polymerase Inhibitors
• Reverse Transcriptase Inhibitors
• Protease Inhibitors
• Neuraminidase Inhibitors
• Others
• Application Outlook (Revenue, USD Billion, 2018 - 2030)
• HIV
• Hepatitis
• Herpes
• Influenza
• Others
• Distribution Channel Outlook (Revenue, USD Billion, 2018 - 2030)
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Drug Class
  • 1.2.3. Application
  • 1.2.4. Distribution Channel
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type
  • 2.2.2. Drug Class
  • 2.2.3. Application
  • 2.2.4. Distribution Channel
• 2.3. Competitive Insights

Chapter 3. U.S. Antiviral Drugs Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. U.S. Antiviral Drugs Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
• 3.4. U.S. Antiviral Drugs Market: Pipeline Analysis

Chapter 4. U.S. Antiviral Drugs Market: Type Estimates & Trend Analysis

• 4.1. Type Segment Dashboard
• 4.2. U.S. Antiviral Drugs Market: Type Movement Analysis
• 4.3. U.S. Antiviral Drugs Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Billion)
• 4.4. Branded
  • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
• 4.5. Generics
  • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 5. U.S. Antiviral Drugs Market: Drug Class Estimates & Trend Analysis

• 5.1. Drug Class Segment Dashboard
• 5.2. U.S. Antiviral Drugs Market: Drug Class Movement Analysis
• 5.3. U.S. Antiviral Drugs Market Size & Trend Analysis, by Drug Class, 2018 to 2030 (USD Billion)
• 5.4. DNA Polymerase Inhibitors
  • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
• 5.5. Reverse Transcriptase Inhibitors
  • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
• 5.6. Protease Inhibitors
  • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
• 5.7. Neuraminidase Inhibitors
  • 5.7.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
• 5.8. Others
  • 5.8.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 6. U.S. Antiviral Drugs Market: Application Estimates & Trend Analysis

• 6.1. Application Segment Dashboard
• 6.2. U.S. Antiviral Drugs Market: Application Movement Analysis
• 6.3. U.S. Antiviral Drugs Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Billion)
• 6.4. HIV
  • 6.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.5. Hepatitis
  • 6.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.6. Herpes
  • 6.6.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.7. Influenza
  • 6.7.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.8. Others
  • 6.8.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 7. U.S. Antiviral Drugs Market: Distribution Channel Estimates & Trend Analysis

• 7.1. Distribution Channel Segment Dashboard
• 7.2. U.S. Antiviral Drugs Market: Distribution Channel Movement Analysis
• 7.3. U.S. Antiviral Drugs Market Size & Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Billion)
• 7.4. Hospital Pharmacy
  • 7.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
• 7.5. Retail Pharmacy
  • 7.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
• 7.6. Online Pharmacy
  • 7.6.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. Key company heat map analysis, 2024
• 8.4. Company Profiles
  • 8.4.1. F. Hoffmann-La Roche Ltd.
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Product benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. GSK plc.
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Product benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. AbbVie, Inc.
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Product benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. Merck & Co., Inc.
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Product benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. Johnson & Johnson Services, Inc.
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Product benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. Bristol-Myers Squibb Company
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Product benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. Cipla Inc.
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Product benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. Aurobindo Pharma
    • 8.4.8.1. Company overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Product benchmarking
    • 8.4.8.4. Strategic initiatives
  • 8.4.9. Dr. Reddy's Laboratories Ltd.
    • 8.4.9.1. Company overview
    • 8.4.9.2. Financial performance
    • 8.4.9.3. Product benchmarking
    • 8.4.9.4. Strategic initiatives
  • 8.4.10. ADARx Pharmaceuticals Inc.
    • 8.4.10.1. Company overview
    • 8.4.10.2. Financial performance
    • 8.4.10.3. Product benchmarking
    • 8.4.10.4. Strategic initiatives